[Pelham]

But sad that hydroxychloroquine is still getting the short shrift, thanks to a Stalinesque campaign of erasing any mention of it.

Actually HCQ is mentioned with approval in the introduction of this paper

"Receptor binding domains (RBD) of the viral spike play a critical role in SARS‐CoV‐2 and ACE2 fusion, so this is a very relevant target complex for viral inhibition.[ 16 ] As described above, various therapeutic strategies have been suggested to inhibit this interaction. Among some of the clinically tested drugs, chloroquine/hydroxychloroquine, arbidol, ribavirin, pensiclovir, favipiravir, nafamostat, nitazoxanide, and camostat mesylate have been shown to decrease virus–host cell binding or cellular internalization or release.

[bagster]

Nicely done, Mr. Pelham.

They ask for the cliff notes, and you provide.